Avidity Biosciences, Inc. will host an investor and analyst event to discuss new data from the MARINA-OLE trial of del-desiran for myotonic dystrophy type 1, showing reversal of disease progression and favorable safety profile.
AI Assistant
AVIDITY BIOSCIENCES INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.